JGC
FULC icon

J. Goldman & Co’s Fulcrum Therapeutics FULC Stock Holding History

J. Goldman & Co’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,100
Closed -$96.7K – 525
2024
Q3 		$96.7K Buy
+27,100
New +$201K ﹤0.01% 429

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's FULC Position: Q4 2025 in Review

J. Goldman & Co sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 135,000 shares — an estimated $1.24M sold.

J. Goldman & Co first reported a position in FULC in Q3 2022 and held it in 7 quarters. The position peaked at $1.24M in Q3 2025. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • J. Goldman & Co reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 135,000 Fulcrum Therapeutics shares in Q4 2025, an estimated $1.24M.
  • J. Goldman & Co first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 7 quarters.
  • J. Goldman & Co's Fulcrum Therapeutics position peaked at $1.24M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.